Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
393.9 USD | +0.21% | -1.49% | -3.10% |
04:21pm | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.10% | 102B | |
+2.21% | 96.84B | |
+0.32% | 21.48B | |
-18.50% | 20.82B | |
-7.26% | 18.6B | |
-40.70% | 16.81B | |
-26.17% | 13.78B | |
+1.59% | 13.4B | |
+22.97% | 11.06B | |
-19.91% | 8.88B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals : Pharma Sheds 10% After VX-864 Drug Candidate Disappoints, But Analysts Still See Value